China’s Health Care Reform Brings New Opportunities
This article was originally published in PharmAsia News
China's new health care reform will bring changes and opportunities to the medical business, according to Business China magazine, mainly in the following aspects: transformation of medicine consumption patterns, expanding the third-tier end-user market; adoption of separate management for drug retail and medical treatment, bringing profit to pharmaceutical channels; improvement of the relationship between drug manufacturers, pharmaceutical companies and end-user buyers; and reduction of demand-supply costs by flattening the distribution channels. The new reform will encourage transparency in the drug purchase system and channels, helping to fight against commercial corruption and decrease pharmaceutical corporations' costs. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.